RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Regeneron Pharmaceuticals Market capitalization 2024

Regeneron Pharmaceuticals Market capitalization

101.65 B USD

Regeneron Pharmaceuticals Dividend yield

Ticker

REGN

ISIN

US75886F1075

WKN

881535

In 2024, Regeneron Pharmaceuticals's market cap stood at 101.65 B USD, a 13.9% increase from the 89.24 B USD market cap in the previous year.

The Regeneron Pharmaceuticals Market capitalization history

YEARREVENUE (undefined USD)GROSS MARGIN (%)NET INCOME (undefined USD)
2029e17.6963,907.08
2028e17.2265,646.55
2027e16.3469,166.09
2026e16.2769,485.79
2025e15.2774,015.3
2024e14.2179,565.02
202313.1286,163.95
202212.1787,184.34
202116.0784,838.08
20208.586,823.51
20197.8690,052.12
20186.7193,532.44
20175.8793,241.2
20164.8693,850.9
20154.190,420.64
20142.8292,730.34
20132.1192,590.42
20121.3893,900.75
20110.4599,10-0.22
20100.4699,56-0.1
20090.3899,74-0.07
20080.24100,00-0.08
20070.13100,00-0.11
20060.0687,30-0.1
20050.0786,36-0.1
20040.1791,380.04

Regeneron Pharmaceuticals Aktienanalyse

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals Inc. is an American biotechnology company founded in 1988 by Leonard Schleifer. The company is headquartered in Tarrytown, New York and employs approximately 8,500 people worldwide. Regeneron is known for its research in the areas of cancer therapies, eye diseases, and asthma. Regeneron operates a business model based on the research and development of biotechnological drugs. The company invests heavily in research and seeks new compounds that can fight inflammation and cancer. Regeneron develops its products using the reverse transcriptase polymerase chain reaction (RT-PCR), a method for amplifying RNA molecules into DNA. This method allows for the rapid production and analysis of large amounts of genetic material. The company is divided into several divisions, including ophthalmology, inflammatory diseases, oncology, and neurology. Regeneron also produces a wide range of biopharmaceutical products, including antibodies, interleukins, enzymes, and fusion proteins. One of Regeneron's most popular products is EYLEA (Aflibercept), a medication used to treat retinal diseases such as age-related macular degeneration. EYLEA has been on the market since 2011 and has proven to be highly effective. The medication is a blockbuster for Regeneron and accounts for a significant portion of its product revenue. Another important product from Regeneron is Dupixent (Dupilumab), a medication used to treat atopic dermatitis and severe asthma. The medication has been on the market since 2017 and has quickly established itself as a key treatment for asthma. Dupixent is produced in collaboration with Sanofi. Regeneron has also conducted promising research in the field of oncology. The company has developed a range of cancer therapies that are in the clinical phase of development. One example is the antibody Libtayo, which is used to treat squamous cell carcinomas. In its recent history, Regeneron has played a major role in the research and development of antibodies for the treatment of COVID-19. Regeneron was the first company to receive funding from the US government for the development of an antibody cocktail for the treatment of COVID-19. The medication, consisting of the antibodies Casirivimab and Imdevimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020. Regeneron also has an extensive partnership with pharmaceutical company Sanofi. The two companies have jointly developed products such as Praluent (Alirocumab), a medication used to lower cholesterol levels, and Kevzara (Sarilumab), a medication used to treat rheumatoid arthritis. Overall, in recent years, Regeneron has built a strong position as a leading biotechnology company. The company has an impressive product pipeline and has developed a wide range of important medications. Regeneron continues to work on the development of new therapies and has the potential to play a significant role in the biotechnology industry in the coming years. Regeneron Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Regeneron Pharmaceuticals revenue by segment

In the annual report of the Regeneron Pharmaceuticals share (US75886F1075, 881535, REGN), it breaks down its revenues into 1 segments: 1. Medicines. The Regeneron Pharmaceuticals stock (WKN: 881535, ISIN: US75886F1075, Ticker Symbol: REGN) is a leading investment for investors interested in participating in the Health Care sector.

Market capitalization Details

Exploring Regeneron Pharmaceuticals's Market Capitalization

Regeneron Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Regeneron Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Regeneron Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Regeneron Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Regeneron Pharmaceuticals Stock

What is the current Regeneron Pharmaceuticals market capitalization?

The current market capitalization of Regeneron Pharmaceuticals is 101.65 B USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Regeneron Pharmaceuticals.

How has the market capitalization of Regeneron Pharmaceuticals developed in recent years?

The market capitalization of Regeneron Pharmaceuticals has increased/decreased by 13.9% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Regeneron Pharmaceuticals?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Regeneron Pharmaceuticals?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Regeneron Pharmaceuticals have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Regeneron Pharmaceuticals pay?

Over the past 12 months, Regeneron Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regeneron Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Regeneron Pharmaceuticals?

The current dividend yield of Regeneron Pharmaceuticals is .

When does Regeneron Pharmaceuticals pay dividends?

Regeneron Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Regeneron Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Regeneron Pharmaceuticals located?

Regeneron Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Regeneron Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Regeneron Pharmaceuticals from 4/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/19/2024.

When did Regeneron Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/19/2024.

What was the dividend of Regeneron Pharmaceuticals in the year 2023?

In the year 2023, Regeneron Pharmaceuticals distributed 0 USD as dividends.

In which currency does Regeneron Pharmaceuticals pay out the dividend?

The dividends of Regeneron Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Regeneron Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Regeneron Pharmaceuticals

Our stock analysis for Regeneron Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regeneron Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.